Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Teva Pharmaceutical Industries Ltd (TEVA)

Teva Pharmaceutical Industries Ltd (TEVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,719,198
  • Shares Outstanding, K 1,092,190
  • Annual Sales, $ 16,659 M
  • Annual Income, $ -3,990 M
  • 60-Month Beta 1.44
  • Price/Sales 0.72
  • Price/Cash Flow 2.80
  • Price/Book 1.06
Trade TEVA with:

Options Overview

Details
  • Implied Volatility 62.94%
  • Historical Volatility 47.81%
  • IV Percentile 76%
  • IV Rank 10.14%
  • IV High 253.94% on 03/18/20
  • IV Low 41.40% on 12/01/20
  • Put/Call Vol Ratio 0.15
  • Today's Volume 4,433
  • Volume Avg (30-Day) 46,038
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 623,120
  • Open Int (30-Day) 817,610

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate 0.57
  • Number of Estimates 4
  • High Estimate 0.61
  • Low Estimate 0.54
  • Prior Year 0.73
  • Growth Rate Est. (year over year) -21.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.39 +5.10%
on 02/23/21
13.30 -17.89%
on 02/09/21
-1.48 (-11.94%)
since 02/03/21
3-Month
9.43 +15.80%
on 12/31/20
13.30 -17.89%
on 02/09/21
+0.94 (+9.42%)
since 12/03/20
52-Week
6.25 +74.72%
on 03/18/20
13.30 -17.89%
on 02/09/21
-0.29 (-2.59%)
since 03/03/20

Most Recent Stories

More News
Teva to Present at the J.P. Morgan 2021 Global High Yield and Leveraged Finance Conference

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Executive Vice President & CFO Eli Kalif will present at the J.P. Morgan 2021 Global High Yield and Leveraged Finance Conference...

JPM : 152.91 (+1.93%)
TEVA : 10.92 (+1.77%)
Varicella Zoster Infection Treatment Market to 2027, Future Outlook, COVID-19 Impact Analysis, Forecast 2021-2027 | Valeant Pharmaceuticals International Inc., Teva Pharmaceutical Industries Ltd, Pfizer Inc. | FMI Report

Future Market Insights (FMI) has published a new report on the titled "Varicella Zoster Infection Treatment Market: Global Industry Analysis 2012 - 2016 and Opportunity Assessment 2017 - 2027." Varicella...

ABT : 119.18 (-2.73%)
GSK : 34.24 (+0.44%)
NVS : 87.56 (-0.69%)
PFE : 34.39 (+2.63%)
TEVA : 10.92 (+1.77%)
VRX.TO : 30.80 (-3.33%)
Global Cancer Pain Management Solutions Market 2020 with Impact of COVID-19 Outbreak, SWOT Study, Steady Growth and Forecast 2025

The latest intelligence report titled explains significant details asked by the customers in terms of industrial advantages or disadvantages and futuristic industry scope. The report offers investigations...

ENDP : 6.85 (-5.26%)
GSK : 34.24 (+0.44%)
TEVA : 10.92 (+1.77%)
VRX.TO : 30.80 (-3.33%)
Amarin (AMRN) Q4 Earnings & Revenues Top, Vascepa Sales Solid

Amarin's (AMRN) revenue growth in the fourth quarter is attributable to continued demand for its cardiovascular drug, Vascepa.

TEVA : 10.92 (+1.77%)
RDY : 60.93 (+0.81%)
AMRN : 5.83 (-3.32%)
SAVA : 48.70 (-5.53%)
New Study Published in Cephalalgia Identifies Mechanistic Differences Among CGRP Migraine Treatments

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) highlights results from the in vitro study "Migraine Therapeutics Differentially Modulate the CGRP Pathway," which were published online by Cephalalgia,...

TEVA : 10.92 (+1.77%)
Hydroxychloroquine Market Size to Hit USD 2,339.1 Million and Grow at 5.5% CAGR by 2027; Increasing Demand for the Product Will provide Impetus to Market Growth, says Fortune Business Insights(TM)

The global hydroxychloroquine market size is projected to reach USD 2,339.1 million by the end of 2027. The increasing incidence of COVID-19 infection will bode well for the market in the coming years....

BAYRY : 15.5100 (-1.96%)
NVS : 87.56 (-0.69%)
TEVA : 10.92 (+1.77%)
Worldwide Cephalosporin Industry to 2026 - by Generation, Route of Administration, Application and Region

, /PRNewswire/ -- The report has been added to offering.

AGN : 193.02 (+0.02%)
BMY : 60.75 (-0.85%)
GSK : 34.24 (+0.44%)
MRK : 73.30 (+0.62%)
NVS : 87.56 (-0.69%)
PFE : 34.39 (+2.63%)
TEVA : 10.92 (+1.77%)
Varicella Zoster Infection Treatment Market Latest Research On Industry Growth, Trends, Top Players, & Key Regions By 2027

The is segmented on the lines of its drug type, route of administration and regional. Basis of drug type is segmented into Acyclovir, Valacyclovir and Famciclovir. Based on route of administration it...

ABT : 119.18 (-2.73%)
GSK : 34.24 (+0.44%)
NVS : 87.56 (-0.69%)
PFE : 34.39 (+2.63%)
TEVA : 10.92 (+1.77%)
VRX.TO : 30.80 (-3.33%)
Acne Drugs Market To 2030 Projected For Healthy Growth Rate By Marketresearch.biz | Allergan Plc, Nestle S.A. (Galderma S.A.)

A consciously conceived and designed business intelligence report titled Global  by Manufacturers, Type, and Application, Forecast to 2030 by discloses a succinct analysis of the regional spectrum,...

AGN : 193.02 (+0.02%)
ADM : 57.12 (-0.44%)
GSK : 34.24 (+0.44%)
NSRGY : 105.5100 (-1.56%)
PFE : 34.39 (+2.63%)
SMGKF : 20.3000 (-3.70%)
TEVA : 10.92 (+1.77%)
VRX.TO : 30.80 (-3.33%)
Acute Kidney Injury Treatment Market will Likely see Expanding of Marketable Business Segment | Novartis AG, Pfizer Inc

A consciously conceived and designed business intelligence report titled Global  by Manufacturers, Type, and Application, Forecast to 2030 by discloses a succinct analysis of the regional spectrum,...

ABLZF : 29.2800 (unch)
CNAT : 0.5560 (+0.18%)
FUJIY : 58.4100 (+0.55%)
IPSEY : 21.2000 (+1.92%)
MRK : 73.30 (+0.62%)
NVS : 87.56 (-0.69%)
PFE : 34.39 (+2.63%)
SIEGY : 79.9600 (+2.05%)
TEVA : 10.92 (+1.77%)
VRX.TO : 30.80 (-3.33%)
WIT : 6.47 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended...

See More

Key Turning Points

3rd Resistance Point 11.14
2nd Resistance Point 11.04
1st Resistance Point 10.88
Last Price 10.92
1st Support Level 10.62
2nd Support Level 10.52
3rd Support Level 10.36

See More

52-Week High 13.30
Last Price 10.92
Fibonacci 61.8% 10.61
Fibonacci 50% 9.77
Fibonacci 38.2% 8.94
52-Week Low 6.25

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar